Literature DB >> 12476896

[The relation between plasma leptin concentration and body fat mass in patients with rheumatoid arthritis].

Anita Tokarczyk-Knapik1, Michał Nowicki, Janusz Wyroślak.   

Abstract

The prospective, cross-sectional study was undertaken to evaluate the relation between the fat mass and serum leptin level in patients with rheumatoid arthritis (RA). Low body mass and anorexia are commonly found in patients with RA. Inflammatory cytokines may significantly influence the secretion of anorectic hormone--leptin--that was confirmed in both experimental and clinical studies. Fifty-two non-diabetic and non-obese patients (38 females, 14 males) were studied. Mean age was 56 +/- 11 years and mean body mass index (BMI) 24.6 +/- 4.1 kg/m2. The disease activity score (DAS) was 3.9 +/- 1.4; range 1.4-7.4, and disease duration 8.1 +/- 6.7 years. Serum leptin was measured by ELISA and body composition by double X-ray densitometry. Mean serum leptin concentration was 2.8 +/- 1.4 ng/ml in patients with RA was lower than in the control group (4.2 +/- 2.0). In a simple regression analysis leptin did not correlate with BMI (R Spearman = 0.01), C-reactive protein (R = 0.08), total fat mass (R = 0.08), trunk fat (R = 0.05), limbs fat (R = 0.09) and DAS (R = -0.17). This relation was also not influenced by gender or type of immunosuppressive therapy. In a multiple regression model none of the independent variables explained the significant portion of variance of serum leptin. It is concluded that the physiologic relation of serum leptin to body fat stores is not present in patients with RA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12476896

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  12 in total

1.  Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis.

Authors:  C Popa; M G Netea; T R D S Radstake; P L van Riel; P Barrera; J W M van der Meer
Journal:  Ann Rheum Dis       Date:  2005-02-24       Impact factor: 19.103

2.  Synovial/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion.

Authors:  Shereen M Olama; Mohammed K Senna; Mohammed Elarman
Journal:  Rheumatol Int       Date:  2010-12-08       Impact factor: 2.631

3.  Adiponectin and leptin serum concentrations in patients with rheumatoid arthritis.

Authors:  Bozena Targońska-Stepniak; Magdalena Dryglewska; Maria Majdan
Journal:  Rheumatol Int       Date:  2009-07-12       Impact factor: 2.631

4.  Leptin serum levels in rheumatoid arthritis patients: relation to disease duration and activity.

Authors:  Bozena Targońska-Stepniak; Maria Majdan; Magdalena Dryglewska
Journal:  Rheumatol Int       Date:  2007-10-30       Impact factor: 2.631

Review 5.  Increased leptin levels in patients with rheumatoid arthritis: a meta-analysis.

Authors:  G Tian; J-N Liang; H-F Pan; D Zhou
Journal:  Ir J Med Sci       Date:  2014-02-09       Impact factor: 1.568

6.  Serum leptin in systemic lupus erythematosus.

Authors:  M Wisłowska; M Rok; K Stepień; A Kuklo-Kowalska
Journal:  Rheumatol Int       Date:  2008-01-15       Impact factor: 2.631

7.  Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis.

Authors:  Arzu Seven; Savaş Güzel; Mahmure Aslan; Vedat Hamuryudan
Journal:  Rheumatol Int       Date:  2008-11-14       Impact factor: 2.631

Review 8.  The role of leptin in innate and adaptive immune responses.

Authors:  Eiva Bernotiene; Gaby Palmer; Cem Gabay
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

9.  Serum leptin in rheumatoid arthritis.

Authors:  Margaret Wisłowska; Mariusz Rok; Bozena Jaszczyk; Krystyna Stepień; Małgorzata Cicha
Journal:  Rheumatol Int       Date:  2007-04-19       Impact factor: 3.580

10.  Relationship Between Leptin and Neopterin Levels and Disease Activation Parameters in Patients With Rheumatoid Arthritis.

Authors:  Arif Gülkesen; Gürkan Akgöl; Türkan Tuncer; Gül Ayden Kal; Selda Telo; Ahmet Kürşad Poyraz; Arzu Kaya
Journal:  Arch Rheumatol       Date:  2016-04-14       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.